Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News TherapeuticsMD Inc TXMD

Healthcare
TherapeuticsMD, Inc. is a pharmaceutical royalty company, which primarily collects royalties from its licensees. It receives royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. It granted a license to commercialize IMVEXXY, BIJUVA, and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD... see more

Recent & Breaking News (NDAQ:TXMD)

TherapeuticsMD Strengthens Board with Appointment of Industry Leaders

Business Wire March 24, 2020

TherapeuticsMD Provides Business Update on COVID-19 Pandemic

Business Wire March 16, 2020

TherapeuticsMD Announces Participation at the Cowen 40th Annual Healthcare Conference

Business Wire February 27, 2020

TherapeuticsMD Announces Fourth Quarter and Full-Year 2019 Financial Results

Business Wire February 20, 2020

TherapeuticsMD and Afaxys Enter Into Agreement to Expand Access to ANNOVERA® in the U.S. Public Health Sector

Business Wire February 13, 2020

TherapeuticsMD to Report Fourth Quarter 2019 Results on February 20, 2020

Business Wire February 10, 2020

TherapeuticsMD Announces Submission of New Drug Application Prior Approval Efficacy Supplement to the U.S. Food and Drug Administration for Lower Dose of BIJUVA®

Business Wire February 3, 2020

TherapeuticsMD, An Innovative Women's Healthcare Company, And PlushCare, A Virtual Health Platform, Announce Enhanced Access To Women's Health Products

PR Newswire January 7, 2020

TherapeuticsMD, an Innovative Women's Healthcare Company, and PlushCare, a Virtual Health Platform, Announce Enhanced Access to Women's Health Products

Business Wire January 7, 2020

TherapeuticsMD Announces Participation at the JP Morgan Healthcare Conference

Business Wire January 6, 2020

TherapeuticsMD Announces Amendment to Term Loan Financing Facility with TPG Sixth Street Partners

Business Wire December 30, 2019

Knight and TherapeuticsMD Announce Filing of New Drug Submission for BIJUVA® in Canada

Business Wire November 26, 2019

TherapeuticsMD Announces Participation at the Stifel 2019 Healthcare Conference

Business Wire November 12, 2019

TherapeuticsMD Announces Third Quarter 2019 Financial Results

Business Wire November 6, 2019

TherapeuticsMD to Report Third Quarter 2019 Results on November 6, 2019

Business Wire November 1, 2019

Knight and TherapeuticsMD Announce Filing of New Drug Submission for Joyesta(TM) in Canada

Business Wire October 30, 2019

TherapeuticsMD Announces Closing of Its Underwritten Public Offering of Common Stock

Business Wire October 29, 2019

TherapeuticsMD Announces Pricing of Its Underwritten Public Offering of 26 Million Shares of Common Stock

Business Wire October 24, 2019

TherapeuticsMD Announces Proposed Underwritten Public Offering of 22 Million Shares of Common Stock

Business Wire October 23, 2019

TherapeuticsMD Announces Estimated Third Quarter 2019 Financial Results

Business Wire October 23, 2019